Libertana Home Health, Orbita team up to offer voice software care assistants

Orbita, providers of voice-first software, and Libertana Home Health, a California-based health and housing waiver management company, have teamed up to develop a home care system that uses Amazon’s Alexa voice assistant technology.

The partnership will utilize Orbita Voice, a software platform for creating and maintaining voice applications for Alexa, to keep users engaged in self-care and daily activities to collect data for home care professionals.

“In our efforts to empower individuals to live independently, Libertana’s had significant success with out-of-the-box approaches. We see great value in the capabilities of voice to address a full range of health and living needs for seniors and disabled individuals,” said Jonathan Istrin, Libertana executive director. “Loneliness, for example, is a huge variable impacting health. At a minimum, if a digital assistant can help break the loneliness cycle, we come out ahead. Beyond this, the possibilities seem nearly endless.”

Libertana is currently conducting test on the virtual assistant in measures including weight, blood pressure, blood sugar levels, mediation. It can also request help from home-care professionals, coordinate transportation and learn about social or recreational activities.

“By enhancing engagement and compliance, voice experiences can contribute to improved outcomes,” said Debra Harrison, RN, Libertana’s public subsidized housing manager. “Voice assistants overcome challenges for individuals who, due to physical limitations, cannot use a keyboard or touch screen. They also improve patient satisfaction with more natural, engaging experiences that eliminate the ‘monitoring’ stigma of other connected devices, while still providing the data-driven insights that improve caregiver response in moments of need and intervention. Finally, they reduce costs by keeping patients at home and away from more costly clinical care settings.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.